Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Greenlight Re Q2 2026 results show CAT drag and BV decline amid buybacks

Aug 4, 2026, 5:30 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The quarter showed a net loss and a meaningful book-value decline, compounded by CAT losses and weaker investment income. While buybacks offer some support for BV, the lack of earnings and ongoing volatility in reinsurance markets historically depress GLRE stock in the near term absent a clear earnings rebound or insurance cycle improvement.

AI summary

What happened, with direct paths to the underlying reporting

Greenlight Capital Re reported a CAT-impacted quarter with a US$29.6 million loss and a drop in fully diluted book value to US$20.61. Premia gains were modest, but investment losses weighed on performance; the company continues buybacks to support BV while capital reserves are kept conservative in a soft market. The next few quarters hinge on CAT activity and investment performance, plus any relief from Solasglas results.

Q2 2026 gross premiums written up 2% to $183.1m; CAT-driven losses widen the combined ratio.
Six months ended June 30, 2026: gross premiums $411.1m, net $316.0m; combined 98.1%.
Net income for Q2: a loss of $29.6m ($0.89/diluted share); BV per share at $20.61, -3.7%.
Greenlight Re accelerated share repurchases: $14.2m in Q2, $19.2m (H1) on avg $17.42.
Management cites volatility, Middle East exposure reserves; Solasglas conservatively positioned; Einhorn notes expensive equity markets.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.